Back to Stocks

ACRS

Aclaris Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Aclaris Therapeutics is strategically transitioning from a discovery-phase entity to a clinical-stage powerhouse, supported by a robust liquidity position of $190.8 million in cash and marketable securities.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the appearance of a strong balance sheet, Aclaris continues to struggle with a widening net loss, which reached $19.8 million this quarter. The company's operational cash burn has increased by 38% year-over-year, highlighting a precarious cash-burn-to-revenue ratio.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ACRS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q reveals a company at a critical juncture, balancing high-risk clinical development with a sophisticated capital management strategy. Aclaris has successfully extended its runway through a $57.9 million ATM offering and the monetization of its Lilly royalties, providing a buffer that exceeds 12 months of operations. However, the increase in R&D spending to $15.7 million underscores the intensifying cost of advancing its pipeline toward pivotal data readouts. Investors are now weighing the potential of a multi-modal pipeline against the reality of sustained operating losses. The upcoming data for bosakitug in Q4 2026 and the Phase 1b results for ATI-052 in the second half of the year will likely serve as the primary determinants of the company's valuation. The central tension remains whether Aclaris can secure a transformative partnership before its current cash reserves are depleted by the escalating costs of late-stage clinical trials.

Selected Quarter

Core Takeaway

The company has secured short-term survival through ATM raises and royalty sales, but remains a binary bet on 2026 clinical data.

Investor Lens

The trade-off between the potential for a massive re-rating on clinical success versus the risk of continued dilution and cash depletion.

Watch Next

Top-line data for bosakitug (ATI-045) expected in Q4 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%
bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise
70%
bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss
60%
bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The latest 10-Q reveals a company at a critical juncture, balancing high-risk clinical development with a sophisticated capital management strategy. Aclaris has successfully extended its runway through a $57.9 million ATM offering and the monetization of its Lilly royalties, providing a buffer that exceeds 12 months of operations. However, the increase in R&D spending to $15.7 million underscores the intensifying cost of advancing its pipeline toward pivotal data readouts. Investors are now weighing the potential of a multi-modal pipeline against the reality of sustained operating losses. The upcoming data for bosakitug in Q4 2026 and the Phase 1b results for ATI-052 in the second half of the year will likely serve as the primary determinants of the company's valuation. The central tension remains whether Aclaris can secure a transformative partnership before its current cash reserves are depleted by the escalating costs of late-stage clinical trials.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.